The Dopamine Allosteric Agent, PAOPA, Demonstrates Therapeutic Potential in the Phencyclidine NMDA Pre-clinical Rat Model of Schizophrenia

The Dopamine Allosteric Agent, PAOPA, Demonstrates Therapeutic Potential in the Phencyclidine NMDA Pre-clinical Rat Model of Schizophrenia

PAOPA, a potent analog of prolyl-leucyl-glycinamide, has shown therapeutic potential at the preclinical stage for dopaminergic related illnesses, including animal models of schizophrenia, Parkinson’s disease and haloperidol-induced extrapyramidal movement disorders. PAOPA’s unique allosteric mechani...

Full description

Bibliographic Details
Main Authors:	Ritesh P. Daya, Jayant Bhandari, Sharnpreet K. Kooner, Joella Ho, Christopher D. Rowley, Nicholas A. Bock, Troy Farncombe, Ram K. Mishra
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2018-12-01
Series:	Frontiers in Behavioral Neuroscience
Subjects:	allosteric modulator dopamine NMDA phencyclidine rat model schizophrenia
Online Access:	https://www.frontiersin.org/article/10.3389/fnbeh.2018.00302/full

Similar Items

Allosteric Inhibitors of NMDA Receptor Functions
by: William F. Borschel, et al.
Published: (2010-10-01)

Altered excitatory-inhibitory balance in the NMDA-hypofunction model of schizophrenia
by: Colin Kehrer, et al.
Published: (2008-04-01)

The Effect of Phencyclidine New Derivatives on Anxiety Behaviors in Rats
by: Ramin Hajkhani, et al.
Published: (2010-04-01)

Phencyclidine: A rare cause of saccadic intrusions
by: M N Shameer Nijam, et al.
Published: (2019-01-01)

Dual Allosteric Effect in Glycine/NMDA Receptor Antagonism: A Comparative QSAR Approach
by: Vipin B. Gupta, et al.
Published: (2010-10-01)

A glutamate concentration‐biased allosteric modulator potentiates NMDA‐induced ion influx in neurons
by: Blaise M. Costa, et al.
Published: (2021-10-01)

Effects of Long-term antipsychotic treatment on enkephalin-immunoreactive neurons in rats perinatally treated with phencyclidine
by: Kompanijec Anja, et al.
Published: (2023-01-01)

Pridopidine Reverses Phencyclidine-Induced Memory Impairment
by: Kristoffer Sahlholm, et al.
Published: (2018-04-01)

Reassessment of amphetamine- and phencyclidine-induced locomotor hyperactivity as a model of psychosis-like behavior in rats
by: Snezana Kusljic, et al.
Published: (2022-01-01)

Phencyclidine Intoxication and Adverse Effects: A Clinical and Pharmacological Review of an Illicit Drug
by: Bey, Tareg, et al.
Published: (2007-02-01)

Targeted NMDA Receptor Interventions for Autism: Developmentally Determined Expression of GluN2B and GluN2A-Containing Receptors and Balanced Allosteric Modulatory Approaches
by: Stephen I. Deutsch, et al.
Published: (2022-01-01)

Profiles of VGF Peptides in the Rat Brain and Their Modulations after Phencyclidine Treatment
by: Barbara Noli, et al.
Published: (2017-06-01)

Haloperidol affects bones while clozapine alters metabolic parameters - sex specific effects in rats perinatally treated with phencyclidine
by: Tatjana Nikolić, et al.
Published: (2017-10-01)

Minimum alveolar concentration of isoflurane in dogs administered a single intramuscular injection of racemic or S (+)-ketamine after premedication with acepromazine-morphine
by: Thais Feres Bressan, et al.

Similarities in the behavior and molecular deficits in the frontal cortex between the neurotensin receptor subtype 1 knockout mice and chronic phencyclidine-treated mice: Relevance to schizophrenia
by: Zhimin Li, et al.
Published: (2010-11-01)

Translational aspects of the novel object recognition task in rats abstinent following sub-chronic treatment with phencyclidine (PCP): effects of modafinil and relevance to cognitive deficits in schizophrenia?
by: John P Redrobe, et al.
Published: (2010-11-01)

Effects of the dopamine D2 allosteric modulator, PAOPA, on the expression of GRK2, arrestin-3, ERK1/2, and on receptor internalization.
by: Dipannita Basu, et al.
Published: (2013-01-01)

Review on allosteric modulators of dopamine receptors so far
by: Fentaw Girmaw
Published: (2024-03-01)

Investigating the Robustness of a Rodent “Double Hit” (Post-Weaning Social Isolation and NMDA Receptor Antagonist) Model as an Animal Model for Schizophrenia: A Systematic Review
by: Khanyiso Bright Shangase, et al.
Published: (2023-05-01)

The Abuse Potential of Novel Synthetic Phencyclidine Derivative 1-(1-(4-Fluorophenyl)Cyclohexyl)Piperidine (4′-F-PCP) in Rodents
by: In Soo Ryu, et al.
Published: (2020-06-01)

Allosteric Modulators of G Protein-Coupled Dopamine and Serotonin Receptors: A New Class of Atypical Antipsychotics
by: Irene Fasciani, et al.
Published: (2020-11-01)

Identification of a Subtype-Selective Allosteric Inhibitor of GluN1/GluN3 NMDA Receptors
by: Yue Zeng, et al.
Published: (2022-06-01)

Allosteric enzymes /
by: Herve, Guy
Published: (1989)

In Silico Prediction and Validation of CB2 Allosteric Binding Sites to Aid the Design of Allosteric Modulators
by: Jiayi Yuan, et al.
Published: (2022-01-01)

Otoimmün anti-NMDA reseptör ensefaliti
by: Osama Shukir Muhammed AMİN
Published: (2018-09-01)

Functional Characterization of the Dopaminergic Psychostimulant Sydnocarb as an Allosteric Modulator of the Human Dopamine Transporter
by: Shaili Aggarwal, et al.
Published: (2021-06-01)

Arylcyclohexylamine Derivatives: Pharmacokinetic, Pharmacodynamic, Clinical and Forensic Aspects
by: Romain Pelletier, et al.
Published: (2022-12-01)

A Swiss army knife for targeting receptors
by: Johansen B Amin, et al.
Published: (2018-05-01)

Ventral midbrain NMDA receptor blockade: from enhanced reward and dopamine inactivation.
by: Giovanni Hernandez, et al.
Published: (2016-08-01)

The positive allosteric modulator of NMDA receptors, GNE‐9278, blocks the ethanol‐induced decrease of excitability in developing retrosplenial cortex neurons from mice
by: Clark W. Bird, et al.
Published: (2023-03-01)

Mechanism of allosteric activation of SIRT6 revealed by the action of rationally designed activators
by: Shaoyong Lu, et al.
Published: (2021-05-01)

Functional Consequences of GPCR Heterodimerization: GPCRs as Allosteric Modulators
by: Karla K.V. Haack, et al.
Published: (2011-03-01)

Disorder driven allosteric control of protein activity
by: Wei-Ven Tee, et al.
Published: (2020-01-01)

Allosteric Modulation of GPCRs of Class A by Cholesterol
by: Jan Jakubík, et al.
Published: (2021-02-01)

Anesthetic care for patients with anti-NMDA receptor encephalitis
by: Faris Al Ghamdi, et al.
Published: (2020-01-01)

Potentiation and allosteric agonist activation of α7 nicotinic acetylcholine receptors: binding sites and hypotheses
by: Victoria R. Sanders, et al.
Published: (2023-05-01)

Comparison of the efficacy of two anticonvulsants, phenytoin and valproate to improve PCP and d-amphetamine induced deficits in a reversal learning task in the rat
by: Nagi F Idris, et al.
Published: (2009-06-01)

Allosteric Regulation of G-Protein-Coupled Receptors: From Diversity of Molecular Mechanisms to Multiple Allosteric Sites and Their Ligands
by: Alexander O. Shpakov
Published: (2023-03-01)

Oscillations and NMDA Receptors: Their Interplay Create Memories
by: Chris Cadonic, et al.
Published: (2014-06-01)

The Molecular Mechanism of Positive Allosteric Modulation at the Dopamine D1 Receptor
by: Alexander Goldberg, et al.
Published: (2023-08-01)